Revolutionary Asthma Treatment: Game-Changer in 50 Years – Everything You Need to Know

A new treatment for asthma attacks has emerged, marking a significant breakthrough after 50 years. Researchers from King’s College London discovered that this injectable treatment can reduce inflammation and lung damage, improving symptoms for patients.

Asthma is a chronic lung condition characterized by airway inflammation, leading to difficulty in breathing. In 2019, it affected about 262 million people worldwide and resulted in roughly 455,000 deaths. Common symptoms include coughing, wheezing, shortness of breath, and chest tightness. Severe episodes are known as asthma attacks.

The new treatment, documented in The Lancet Respiratory Medicine, dampens part of the immune system that can become overactive during asthma flare-ups and chronic obstructive pulmonary disease (COPD). The existing drug, Benralizumab, is currently used for severe asthma cases. New findings suggest it could be beneficial for a broader range of asthma patients, potentially preventing nearly two million attacks annually in the UK.

The research indicates that different immune responses occur in various patients during asthma or COPD attacks. According to Prof. Mona Bafadhel, understanding these inflammation patterns allows for better treatment matching for patients.

### What is Benralizumab? How It Works

Benralizumab, related to the brand name Fasenra, is a monoclonal antibody targeting a specific receptor (CD125) on eosinophils, a type of white blood cell that contributes to inflammation in asthma. Approved by the FDA in November 2017 for severe eosinophilic asthma, it is also designated for eosinophilic esophagitis as of August 2019. The drug effectively manages severe asthma attacks characterized by wheezing, coughing, and chest tightness.

### Study Findings

In a study involving 158 participants, researchers monitored patients over three months following treatment for asthma flare-ups. Results showed that those treated with the new medication were less likely to require hospitalization, need additional treatments, or face fatal outcomes. Prof. Bafadhel described this development as a revolutionary change in treatment after decades, leading to improved patient quality of life.

What are the potential benefits of Benralizumab for asthma patients compared to conventional treatments?

Interview with Prof. Mona Bafadhel on Revolutionary Asthma Treatment

News directory 3: Thank you for joining us today, Prof. Bafadhel. The recent discovery of an injectable treatment for asthma is remarkable. Can you share how this new treatment, based on Benralizumab, represents a breakthrough after 50 years?

prof. Mona bafadhel: Thank you for having me. Yes, this discovery is indeed pivotal. For decades, we have been limited in our options for treating asthma effectively during severe attacks. Our research indicates that Benralizumab, which has been used primarily for severe asthma cases, can now potentially benefit a broader population by addressing the overactive immune responses that precipitate asthma flare-ups and COPD attacks.

News Directory 3: What are the key findings from your recent study, and how do they impact asthma management?

Prof. Mona Bafadhel: In our study involving 158 participants, we administered the treatment and monitored it’s effects over three months. We found that patients receiving Benralizumab were significantly less likely to be hospitalized or require additional treatments, which speaks to its efficacy in reducing severe asthma episodes. This has the potential to enhance the quality of life for many patients and could prevent nearly two million asthma attacks annually in the UK alone.

News Directory 3: Asthma affects millions globally. What are the broader implications of your findings for public health?

Prof. Mona Bafadhel: Our findings highlight the importance of personalized treatment approaches. by understanding the distinct inflammation patterns in patients during asthma attacks, we can tailor treatments more effectively. This could not only lead to better management of asthma but also reduce healthcare costs and improve overall public health outcomes.

News Directory 3: Benralizumab targets eosinophils specifically. Can you explain how this mechanism works and why it’s effective?

Prof. Mona Bafadhel: Certainly. Benralizumab is a monoclonal antibody that targets the CD125 receptor on eosinophils,a type of white blood cell that plays a significant role in asthma-related inflammation. By dampening the activity of eosinophils,we can mitigate the inflammatory response that causes airway constriction and improves breathing difficulties.

News Directory 3: What should patients know about potential side effects and the overall safety of Benralizumab?

Prof. Mona Bafadhel: As with any medication, Benralizumab can cause side effects, including chest tightness, difficulty breathing, and skin reactions. It’s crucial for patients to discuss these potential side effects with their healthcare providers before starting treatment. However, the benefits in preventing severe asthma attacks often outweigh the risks, making it a valuable option for many.

News Directory 3: Lastly, what does the future hold for asthma research and treatment?

Prof. Mona Bafadhel: The future is promising. We’re entering an era of more targeted therapies that cater to individual patients’ needs. Continued research into asthma and related conditions will help us refine these treatments and further improve patient outcomes. Our study on Benralizumab is just the beginning of what we hope will be a series of advances in asthma management.

News Directory 3: Thank you, Prof. Bafadhel, for sharing your insights on this groundbreaking advancement in asthma treatment.

prof.Mona bafadhel: Thank you for having me.

### Common Side Effects

Possible side effects of Benralizumab include:

– Chest tightness
– Difficulty breathing or swallowing
– Fast heartbeat
– Hives or skin rash
– Hoarseness
– Joint pain or swelling
– Redness or swelling of the skin
– Swelling of the face, eyelids, lips, hands, or feet